CureVac N.V.

NasdaqGM:CVAC 株式レポート

時価総額：US$780.6m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

CureVac マネジメント

マネジメント 基準チェック /24

CureVac'sの CEO はAlexander Zehnderで、 Apr2023年に任命され、 の在任期間は 1.17年です。 の年間総報酬は€ 978.33Kで、 51.1%給与と48.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.025%を直接所有しており、その価値は$ 196.16K 。経営陣と取締役会の平均在任期間はそれぞれ1.4年と8.3年です。

主要情報

Alexander Zehnder

最高経営責任者

€978.3k

報酬総額

CEO給与比率51.1%
CEO在任期間1.2yrs
CEOの所有権0.03%
経営陣の平均在職期間1.4yrs
取締役会の平均在任期間8.3yrs

経営陣の近況

Recent updates

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01
Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

CureVac BV reports Q2 results

Aug 18

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

Jul 05

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac: Wait For Concrete News Before Investing

Sep 01

CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy

Jun 16

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02
CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

Mar 03
How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma

Feb 04

Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

Jan 27
Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates

Jan 11

CureVac, Bayer agree to COVID-19 vaccine alliance - report

Jan 07

CEO報酬分析

CureVac の収益と比較して、Alexander Zehnder の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-€273m

Dec 31 2023€978k€500k

-€260m

報酬と市場: Alexanderの 総報酬 ($USD 1.05M ) は、 US市場 ($USD 3.40M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Alexanderの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Alexander Zehnder (54 yo)

1.2yrs

在職期間

€978,331

報酬

Dr. Alexander Zehnder, M.D, MBA, is Chief Executive Officer at CureVac N.V. since April 01, 2023 and is its Managing Director since March 2023 and serves as its Member of Management Board since 2023. He se...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Alexander Zehnder
CEO, MD & Member of Management Board1.2yrs€978.33k0.025%
€ 196.2k
Pierre Kemula
MD, CFO & Member of Management Board7.7yrs€654.18k0.035%
€ 275.0k
Malte Greune
COO, Member of Management Board & MD2.9yrs€600.74k0.0038%
€ 29.7k
Myriam Mendila
Chief Scientific Officer1.4yrs€614.49k0.0021%
€ 16.5k
Ulrike Gnad-Vogt
Senior VP & Area Head of Oncology1.4yrs€284.15k0%
€ 0
Sarah Fakih
Vice President Corporate Communications & Investor Relationsno dataデータなしデータなし
Marco Rau
General Counselno dataデータなしデータなし
Thorsten Schuller
Head of Corporate Communicationsno dataデータなしデータなし
Slavica Stevanovic-Heck
Head of Human Resourcesno dataデータなしデータなし
Patrick Baumhof
Senior Vice President of Technologyno dataデータなしデータなし
Ronald Plasterk
Senior Vice President of Science & Innovationno dataデータなしデータなし
Marcus Dalton
Head of Intellectual Propertyno dataデータなしデータなし

1.4yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: CVACの経営陣は 経験豊富 とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Hans-Georg Rammensee
Scientific Director of Immunology and Member of Scientific Advisory Boardno dataデータなしデータなし
Craig Tooman
Supervisory Board Member5yrs€96.25k0.0043%
€ 33.6k
Karim Fizazi
Member of Scientific Advisory Board8.3yrsデータなしデータなし
Michael Brosnan
Independent Director of Supervisory Boardless than a year€51.03k0.0019%
€ 14.6k
Baron Stephenne
Independent Chairman of Supervisory Board8.8yrs€123.75k0.0075%
€ 58.3k
Nina Bhardwaj
Member of Scientific Advisory Board8.3yrsデータなしデータなし
Stanley Plotkin
Member of Scientific Advisory Board8.3yrsデータなしデータなし
Michael Manns
Member of Scientific Advisory Board8.3yrsデータなしデータなし
Jean-Paul Prieels
Member of Scientific Advisory Board8.3yrsデータなしデータなし
Mathias Hothum
Supervisory Board Member8.8yrs€96.25k0.0048%
€ 37.7k
Dirk Jäger
Member of Scientific Advisory Board8.3yrsデータなしデータなし
Christopher Karp
Member of Scientific Advisory Board8.3yrsデータなしデータなし

8.3yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: CVACの 取締役会 は 経験豊富 であると考えられます ( 8.3年の平均在任期間)。